Navigation Links
Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- Baxter International Inc. today announced final Phase I/II data for its adjuvant-free investigational pandemic H5N1 influenza vaccine and plans to initiate a Phase III clinical trial of the candidate vaccine in Europe to confirm the study results.

The Phase I/II study indicated that Baxter's H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains. The open-label, multi-center Phase III trial is designed to evaluate the safety and efficacy of Baxter's adjuvant-free, whole-virus candidate vaccine. Vaccinations will begin in the first half of this year and results of the Phase III trial are scheduled to be available by the end of 2007.

"The results of the Phase I/II clinical trial suggested that this candidate vaccine may provide protection against divergent strains of virus, even at low dose levels without an adjuvant," said John Oxford, professor of Virology, The Queen Mary School of Medicine, London, United Kingdom. "The Phase III clinical trial is designed to confirm these findings and provide a solid measure of the vaccine's potential to protect a large number of people before and during a possible pandemic."

Baxter's candidate H5N1 vaccine is derived from H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure closely resembles the actual pathogen circulating in nature. The candidate vaccine induces an immune response (both cell and antibody mediated) that is similar to the body's defense against a natural virus, without the need to incorporate additional agents (adjuvants) to enhance immune response. It is manufactured using the company's proprietary vero cell technology, which produces high- yield vaccine more quickly than traditional approaches because it is not produced in eggs. Baxter's candidate vaccine is the first cell-
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... several clinical studies evaluating potential new medicines in ... the upcoming 2014 European Society of Medical Oncology ... Madrid, Spain . Data being presented include ... safety and efficacy of veliparib (ABT-888), a poly ...
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... -- According to the new market ... Media and Reagents), by Source, by type, by ... Testing, Research, Drug Discovery) - Analysis & Global ... studies the major market drivers, threats, opportunities, and ... tables and 64 figures spread through 225 pages ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... YORK, May 22, 2012  Fox Insurance Company, a Medicare ... announces the confirmation of a judgment in the arbitration ... manager, in excess of $3.3 million, following a suit ... breach of contract.  On May 21, 2012, the U.S. ...
Denmark...
Cached Medicine Technology:Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... intensive care units (NICU) set up private rooms for parents ... Researchers at one children,s hospital found that preemies gained ... their NICU switched from the traditional "open-bay" layout to private ... in the journal Pediatrics , add to evidence that ...
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... Many American parents are aware of online physician-rating sites, and ... for their children, according to a new national study. ... parents -- further suggest that negative online ratings may dissuade ... been recommended by a neighbor. Conversely, a positive online ...
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... scientists have found that an anticonvulsant drug may help ... Although dozens of antibiotics target what bacteria do, their ... bacteria are created, and they found there is a ... important as there is growing concern worldwide about how ... The World Health Organization has declared that antibiotic resistance ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2
... Many baby boomers,incorrectly believe they have disability income ... Interactive(R) on behalf of America,s Health,Insurance Plans (AHIP). ... their income, but nearly half say they do ... http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), "Baby boomers recognize the ...
... JUPITER, Fla., May 22 Atlas Spine, Inc., ... fusion and non-fusion,products, announced today the national launch ... VBR is a radiolucent MIS compatible spacer,system designed ... of,various pathologies of the thoracic and lumbar spine., ...
... As Part Of Its Summer-Long Harley-Davidson ... 105th Anniversary Celebration Promotion, MILWAUKEE, May 22 ... Association (MDA) for every Miller Lite,bottle cap collected now through ... promotion. Miller Lite, the "ultimate light beer,",is the official beer ...
... 2008) The Foundation of the National Student Nurses ... New Jersey Regional Faculty Fellowships to two Rutgers College ... , The fellowship will help Ho-Shing, a Union, N.J. ... tuition, academic fees, and book expenses during the Fall ...
... Parental Reassurance, NEW YORK, May 22 ... biosensor and microprocessor technologies for,use in portable monitoring ... its latest homecare wellness product using SPO,s patented,technology ... home baby,monitor market., Each year, there are ...
... $4 MILLION INVESTMENT WILL SUPPORT AMERICA,S NEW GENERATION ... The National,Alliance for Hispanic Health (the Alliance) announced ... a new,partnership improving Hispanic student access to higher ... (STEM). The Program is,made possible through a $4 ...
Cached Medicine News:Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 3Health News:Atlas Spine Launches Stature(TM) Vertebral Body Replacement System 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 3Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
... proteins that suppress the secretion of FSH ... consists of two distinct chains, or subunits ... consists of the alpha-subunit and betaA-subunit. Inhibin ... Only the dimeric forms of the molecule, ...
Medicine Products: